Supporting Information

Direct Dehydrogenative Alkyl Heck-Couplings of Vinylarenes with Umpolung Aldehydes Catalyzed by Nickel

Lv et al

Supplementary Notes

¹H NMR spectra were recorded on Bruker 400 or 500 MHz spectrometer and the chemical shifts were reported in parts per million (δ) relative to internal solvent signal (7.28 ppm in CDCl₃). The peak patterns are indicated as follows: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet. The coupling constants, *J*, are reported in Hertz (Hz). ¹³C NMR spectra were obtained at 100 or 125 MHz and referenced to the internal solvent signal (central peak is 77.0 ppm in CDCl₃). CDCl₃ was used as the NMR solvent. Flash column chromatography was performed over silica gel 200-300. The reagent Ni(cod)₂ were weighed and handled in a glovebox. All reagents were purchased from Alfa, Acros, Aldrich, and TCI and used without further purification. The HRMS measurements were recorded on a TOF analyzer using an ESI or APCI source in the positive mode. [Warning: hydrazine monohydrate is potentially hazardous and should be performed with appropriate personal protection].

0	N ₂ H ₄ ·H ₂ O N ^{-N}	JH ₂	catalyst (10 mol%) ligand, DIPEA	<u>∧</u> ∕∧
Ph	rt, 30 min Ph	+ 🛩 Ph	THF, 100 °C, 12 h	° Ph′ ❤∕ `P
1a	2a	3a		4aa
entry	catalyst	ligand	base	4aa (%)
1	Ni(cod) ₂	PEt ₃	DIPEA	N.D.
2	Ni(cod) ₂	PBu ₃	DIPEA	N.D.
3	Ni(cod) ₂	dppf	DIPEA	N.D.
4	Ni(cod) ₂	dmpe	DIPEA	N.D.
5	Ni(cod) ₂	dppp	DIPEA	N.D.
6	Ni(cod) ₂	Ruphos	DIPEA	trace
7	Ni(cod) ₂	Davepho	s DIPEA	N.D.
8	Ni(cod) ₂	DPEphos	B DIPEA	trace
9	Ni(cod) ₂	X-phos	DIPEA	trace
10	Ni(cod) ₂	Xanphos	DIPEA	N.D.
11	Ni(cod) ₂	rac-BINA	P DIPEA	N.D.
12	Ni(cod) ₂	cataCXiu	IM A DIPEA	N.D.
13	Ni(cod) ₂	SIPrHCI	DIPEA	trace
14	Ni(cod) ₂	IPr •HCI	DIPEA	trace
15	Ni(cod) ₂	IPr•HCI	DIPEA	trace
16	Ni(cod) ₂	bipy	DIPEA	trace
17	Ni(cod) ₂	1,10-phenanthr	oline DIPEA	N.D.
18	Ni(cod) ₂	triphos	DIPEA	N.D.
19	Ni(cod) ₂	dcype	^t BuOK	N.D.
20	Ni(cod) ₂	dcype	K ₃ PO ₄	N.D.
21	Ni(cod) ₂	dcype	Cs_2CO_3	N.D.
22	Ni(cod) ₂	dcype	DABCO	44 (79:21)
23	Ni(cod) ₂	dcype	Et ₃ N	62 (77:23)
24	Ni(cod) ₂	dcype	DBU	42 (82:18)
25	NiCl ₂	dcype	DIPEA	trace
26	NiBr ₂ •diglym	e dcype	DIPEA	trace
27	Ni(acac) ₂	dcype	DIPEA	10 (78:22)
28	Pd(OAc) ₂	dcype	DIPEA	N.D.
29	CuCl ₂	dcype	DIPEA	N.D.
30	CoCl ₂	dcype	DIPEA	N.D.

Supplementary Table 1 Optimization of the reaction conditions

Reaction conditions: **3a** (0.2 mmol), **1a** (0.6 mmol), $N_2H_4 \cdot H_2O$ (0.72 mmol), $Ni(cod)_2$ (10 mol%), ligand (20 mol%) for monodentate, 10 mol% for bidentate), base (0.4 mmol), THF (1.0 mL), 100 °C, 12 h under N_2 unless other noted. NMR yields were determined by ¹H NMR using mesitylene as an internal standard and based on **3a**. The *E*:Z ratio was determined by ¹H NMR analysis of the crude mixture. N.D.= not detected.

Supplementary Methods

Experimental procedures

In situ preparation of hydrazone solution 2: a mixture of aldehydes 1 (0.6 mmol, 3.0 equiv) and hydrazine monohydrate (36 μ L, 0.72 mmol, 64–65 wt%, 3.6 equiv) in THF (0.6 mL) solution was stirred for 30 min at room temperature in air. Before use, a small amount of anhydrous Na₂SO₄ and 4Å MS was added.

In a glovebox, a flame-dried reaction tube (10 cm^3) equipped with a magnetic stir bar was charged with Ni(cod)₂ (5.6 mg, 10 mol%), dcype (8.5 mg, 10 mol%) and THF (0.4 mL) before being sealed with a rubber septum. The reaction mixture was stirred at room temperature for 30 min. Then vinylarene **3** (0.2 mmol, 1.0 equiv), hydrazone solution **2** (0.6 mmol in 0.6 mL THF), DIPEA (0.4 mmol, 67 µL) and NaI (0.1 mmol, 15 mg) was added sequentially. After that, the reaction mixture was sealed with aluminum cap, moved out of glovebox, and stirred at 100 °C for 12 hour. After the mixture was cooled to room temperature, the resulting solution was directly filtered through a pad of silica by EtOAc (3.0 mL). The crude mixture was analyzed by GC-MS. The solvent was evaporated *in vacuo* to give the crude products. NMR yields were determined by ¹H NMR using mesitylene as an internal standard. The residue was purified by preparative TLC (ethyl acetate/petroleum ether) to give the pure product.

Data analyst

Ph

(*E*)-Prop-1-ene-1,3-diyldibenzene (4aa). (34 mg, 87%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 7.43-7.23 (m, 10H), 6.52 (d, *J* = 16.0 Hz, 1H), 6.45-6.38 (m, 1H), 3.61 (d, *J* = 7.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 140.2, 137.5, 131.1, 129.3, 128.7, 128.5, 127.1, 126.2, 126.1, 39.4; EI-MS (m/z): 194.2. The spectroscopic data for this product match the literature data.^[1]

Ph

(*E*)-1-Methyl-4-(3-phenylprop-1-en-1-yl)benzene (4ab). (37 mg, 89%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.42-7.13 (m, 9H), 6.47 (d, *J* = 15.8 Hz, 1H), 6.40-6.32 (m, 1H), 3.58 (d, *J* = 6.8 Hz, 2H), 2.36 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 140.3, 136.8, 134.7, 130.9, 129.2, 128.7, 128.5, 128.2, 126.1, 126.0, 39.4, 21.2; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[2]



(*E*)-1-Methyl-3-(3-phenylprop-1-en-1-yl)benzene (4ac). (41 mg, 84%). Isolated by preparative TLC (hexane, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.31 (m, 3H), 7.27-7.05 (m, 6H), 6.46 (d, *J* = 15.6 Hz, 1H), 6.42-6.35 (m, 1H), 3.58 (d, *J* = 6.6 Hz, 2H), 2.36 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 140.3, 138.1, 137.4, 131.1, 129.0, 128.6, 128.5, 128.4, 127.9, 126.8, 126.1, 123.3, 39.4, 21.4; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[2]



(*E*)-1,4-Dimethyl-2-(3-phenylprop-1-en-1-yl)benzene + 2-cinnamyl-1,4-dimethylbenzene (4ad). (combined 39.1 mg, 88%, 57:43). Isolated by preparative TLC (hexane, $R_f = 0.5$); Major and minor: ¹H NMR (500 MHz, CDCl₃) δ 7.39-7.22 (m, 6H), 7.11-7.05 (m, 1H), 7.01-6.97 (m, 1H), 6.69 (d, *J* = 15.6 Hz, 0.4H), 6.44-6.22 (m, 1.6H), 3.61 (d, *J* = 6.8 Hz, 1H), 3.53 (d, *J* = 5.3 Hz, 1H), 2.34 (s, 3.1H), 2.33 (s, 2.9H); Major and minor: ¹³C NMR (125 MHz, CDCl₃) δ 140.4, 138.0, 137.6, 136.3, 135.5, 135.3, 133.2, 132.0, 130.8, 130.2, 130.1, 130.2, 129.1, 128.7, 128.5, 127.8, 127.1, 127.2, 126.2, 126.1, 39.7, 36.9, 21.0, 19.4, 19.0; EI-MS (m/z): 222.1. The spectroscopic data for this product match the literature data.^[3]



(*E*)-1-(*Tert*-butyl)-4-(3-phenylprop-1-en-1-yl)benzene (4ae). (44.5 mg, 89%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.38-7.23 (m, 9H), 6.49 (d, *J* = 15.8 Hz, 1H), 6.43-6.34 (m, 1H), 3.59 (d, *J* = 7.4 Hz, 2H), 1.36 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 150.2, 140.4, 134.7, 130.9, 128.7, 128.5, 128.4, 126.2, 125.9, 125.5, 39.4, 34.5, 31.3; EI-MS (m/z): 250.2. The spectroscopic data for this product match the literature data.^[2]



(*E*)-4-(3-Phenylprop-1-en-1-yl)-1,1'-biphenyl (4af). (43.8 mg, 81%). Isolated by preparative TLC (hexane, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.65-7.58 (m, 5H), 7.49-7.46 (m, 3H), 7.40-7.35 (m, 4H), 7.33-7.30 (m, 2H), 6.55 (d, *J* = 15.8 Hz, 1H), 6.49-6.43 (m, 1H), 3.63 (d, *J* = 7.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 140.8, 140.2, 139.9, 136.6, 130.7, 129.5, 128.8, 128.7, 128.6, 127.3, 126.9, 126.6, 126.3, 39.5; EI-MS (m/z): 270.2. The spectroscopic data for this product match the literature data.^[2]

Ph ОМе

(*E*)-1-Methoxy-4-(3-phenylprop-1-en-1-yl)benzene (4ag). (38.5 mg, 86%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.37-7.24 (m, 7H), 6.88 (d, *J* = 8.7 Hz, 2H), 6.45 (d, *J* = 15.6 Hz, 1H), 6.29-6.24 (m, 1H), 3.84 (s, 3H), 3.58 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 158.9, 140.5, 130.5, 130.4, 128.7, 128.6, 127.3, 127.1, 126.2, 113.9, 55.4, 39.4; EI-MS (m/z): 224.1. The spectroscopic data for this product match the literature data.^[2]



(*E*)-1,2-Dimethoxy-4-(3-phenylprop-1-en-1-yl)benzene (4ah). (44.2 mg, 87%). Isolated by preparative TLC (hexane: ethyl acetate = 20:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.26 (m, 6H), 6.96-6.80 (m, 2H), 6.44 (d, *J* = 15.7 Hz, 1H), 6.30-6.24 (m, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.58 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 149.0, 148.5, 140.4, 130.9, 130.7, 128.7, 128.5, 127.4, 126.2, 119.2, 111.2, 108.6, 56.0, 55.8, 39.4; EI-MS (m/z): 254.1. The spectroscopic data for this product match the literature data.^[2]



(*E*)-1-Fluoro-4-(3-phenylprop-1-en-1-yl)benzene (4ai). (40.7 mg, 96%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.38-7.33 (m, 4H), 7.30-7.24 (m, 3H), 7.06-7.01 (m, 2H), 6.46 (d, *J* = 15.8 Hz, 1H), 6.32 (dt, *J* = 15.8, 6.7 Hz, 1H), 3.59 (d, *J* = 6.7 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 162.0 (d, *J*_{C-F} = 244.6 Hz), 140.0, 133.6 (d, *J*_{C-F} = 3.1 Hz), 129.8, 129.0, 128.6, 128.5, 127.5 (d, *J*_{C-F} = 7.8 Hz), 126.2, 115.3 (d, *J*_{C-F} = 21.4 Hz), 39.3; ¹⁹F NMR (470 MHz, CDCl₃) δ -115.3; EI-MS (m/z): 212.1. The spectroscopic data for this product match the literature data.^[2]



(*E*)-1-(3-Phenylprop-1-en-1-yl)-4-(trifluoromethyl)benzene (4aj). (41.4 mg, 79%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.56 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 7.39-7.25 (m, 5H), 6.52-6.46 (m, 2H), 3.60 (d, J = 4.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 140.9, 139.6, 132.1, 129.8, 128.9 (q, $J_{C-F} = 32.4$ Hz), 128.7, 128.6, 126.4, 126.3, 125.5 (q, $J_{C-F} = 3.8$ Hz), 124.3 (q, $J_{C-F} = 271.8$ Hz), 39.4; ¹⁹F NMR (470 MHz, CDCl₃) δ -62.5; EI-MS (m/z): 262.1. The spectroscopic data for this product match the literature data.^[2]

Ph

(*E*)-4-(3-phenylprop-1-en-1-yl)phenol (4ak). (29 mg, 69%). Isolated by preparative TLC (hexane: ethyl acetate = 3:1, $R_f = 0.5$); ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.33 (m, 3H), 7.29-7.25 (m, 3H), 6.83-6.78 (m, 3H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.24 (dt, *J* = 15.8, 6.8 Hz, 1H), 4.88 (br, 1H), 3.56 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃)

 δ 154.7, 140.5, 130.4, 129.8, 128.7, 128.5, 127.5, 127.2, 126.1, 115.4, 39.3; EI-MS (m/z): 210.1. The spectroscopic data for this product match the literature data.^[4]



(*E*)-4-(3-Phenylprop-1-en-1-yl)phenyl acetate (4al). (32.3 mg, 64%). Isolated by preparative TLC (hexane:ethyl acetate = 20:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.40-7.38 (m, 2H), 7.36-7.24 (m, 5H), 7.06-7.04 (m, 2H), 6.47 (d, *J* = 15.6 Hz, 1H), 6.40-6.31 (m, 1H), 3.57 (d, *J* = 6.7 Hz, 2H), 2.32 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.5, 149.7, 140.1, 135.3, 130.1, 129.6, 129.5, 128.7, 128.5, 127.0, 126.1, 121.6, 39.3, 21.1; EI-MS (m/z): 252.1. The spectroscopic data for this product match the literature data.^[5]



(*E*)-4-(3-Phenylprop-1-en-1-yl)aniline (4am). (31 mg, 74%). Isolated by preparative TLC (hexane:ethyl acetate = 3:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.35-7.22 (m, 5H), 7.21 (d, *J* = 8.4 Hz, 2H), 6.65 (d, *J* = 8.4 Hz, 2H), 6.40 (d, *J* = 15.6 Hz, 1H), 6.19 (dt, *J* = 15.6, 6.8 Hz, 1H), 3.67 (br, 2H), 3.55 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 145.6, 140.7, 130.8, 128.7, 128.5, 128.3, 127.2, 126.0, 125.6, 115.2, 39.4; EI-MS (m/z): 209.1. The spectroscopic data for this product match the literature data.^[6]



(*E*)-*N*-(4-(3-Phenylprop-1-en-1-yl)phenyl)acetamide (4an). (46.7 mg, 93%). Isolated by preparative TLC (dichloromethane: methanol = 30:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.46 (d, *J* = 8.4 Hz, 2H), 7.42 (br, 1H), 7.38-7.30 (m, 4H), 7.27 (d, *J* = 8.4 Hz, 2H), 7.25-7.20 (m, 1H), 6.43 (d, *J* = 15.6 Hz, 1H), 6.38-6.28 (m, 1H), 3.56 (d, *J* = 6.8 Hz, 2H), 2.18 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.3, 140.2, 136.9, 133.7, 130.4, 129.2, 128.7, 128.5, 126.7, 126.2, 119.9, 39.3, 24.6; EI-MS (m/z): 251.1. The spectroscopic data for this product match the literature data.^[6]



(*E*)-2-(3-Phenylprop-1-en-1-yl)naphthalene (4ao). (41 mg, 84%). Isolated by preparative TLC (hexane, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.83-7.79 (m, 3H), 7.74 (s, 1H), 7.62 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.50-7.25 (m, 7H), 6.66 (d, *J* = 15.7 Hz, 1H), 6.57-6.50 (m, 1H), 3.65 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 140.2, 135.0, 133.7, 132.8, 131.2, 129.8, 128.8, 128.6, 128.2, 127.9, 127.7, 126.3, 126.2, 125.8, 125.6, 123.6, 39.5; EI-MS (m/z): 244.1. The spectroscopic data for this product match the literature data.^[2]



Prop-1-ene-1,1,3-triyltribenzene (**4ap**). (25.9 mg, 48%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.44-7.41 (m, 2H), 7.38-7.22 (m, 13H), 6.30 (t, *J* = 7.6 Hz, 1H), 3.51 (d, *J* = 7.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 142.5, 142.4, 141.0, 139.8, 129.9, 128.5, 128.4, 128.3, 128.1, 127.8, 127.4, 127.2, 127.1, 126.0, 35.9; EI-MS (m/z): 270.1. The spectroscopic data for this product match the literature data.^[7]



But-3-ene-1,3-diyldibenzene (4aq) and (*E***)-But-2-ene-1,3-diyldibenzene (4aq'). (combined 26.6 mg, 64%, 60:40). Isolated by preparative TLC (hexane, R_f = 0.7); Major (4aq)**: ¹H NMR (500 MHz, CDCl₃) 7.52-7.23 (m, 10H), 5.36 (d, *J* = 0.9 Hz, 1H), 5.13 (d, *J* = 0.9 Hz, 1H), 2.91-2.81 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 147.8, 141.9, 141.0, 128.4, 128.3, 127.4, 126.1, 125.8, 112.7, 37.2, 34.7. **Minor (4aq')**: ¹H NMR (500 MHz, CDCl₃) δ 147.8, 7.52-7.25 (m, 10H), 6.04 (tq, *J* = 7.4, 1.3 Hz, 1H), 3.64 (d, *J* = 7.4 Hz, 2H), 2.21 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 143.6, 141.1, 135.7, 128.4, 128.3, 126.7, 126.6, 125.9, 125.7, 34.9, 16.0; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[6]



(*Z*)-(2-Methylprop-1-ene-1,3-diyl)dibenzene (4ar) and (*E*)-(2-Methylprop-1-ene-1,3-diyl)dibenzene (4ar'). (combined 14.6 mg, 35%, 67:33). Isolated by preparative TLC (hexane, $R_f = 0.7$); Major: ¹H NMR (500 MHz, CDCl₃) 7.35-7.30 (m, 6H), 7.25-7.21 (m, 4H), 6.55 (s, 1H), 3.64 (s, 2H), 1.84 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 139.7, 138.2, 137.0, 128.6, 128.5, 128.4, 128.2, 127.4, 126.3, 126.0, 38.5, 24.0; Minor: ¹H NMR (500 MHz, CDCl₃) δ 7.35-7.30 (m, 6H), 7.25-7.21 (m, 4H), 6.41 (s, 1H), 3.51 (s, 2H), 1.83 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 139.8, 138.4, 138.1, 129.0, 128.9, 128.3, 128.0, 126.8, 126.2, 126.1, 47.1, 17.6; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[8]



1-Cinnamyl-4-fluorobenzene (4ba). (38.3 mg, 92%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 7.43-7.13 (m, 9H), 6.48 (d, J = 15.8 Hz, 1H), 6.38 (dt, J = 15.8, 6.7 Hz, 1H), 3.55 (d, J = 6.7 Hz, 2H), 2.37 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 137.5, 137.1, 135.7, 130.8, 129.5, 129.2, 128.5, 127.0, 126.1, 38.9, 21.0; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[9]



1-Cinnamyl-2-methylbenzene (4bb). (37.0 mg, 89%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, J = 7.6 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.24-7.19 (m, 5H), 6.44-6.34 (m, 2H), 3.57 (d, J = 5.1 Hz, 2H), 2.37 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 138.2, 137.5, 136.4, 131.0, 130.2, 129.2, 128.8,

128.7, 127.0, 126.4, 126.1, 126.0, 36.8, 19.4; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[9]



1-Cinnamyl-3-methylbenzene (4bc). (39.1 mg, 94%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 7.40 (dd, J = 7.6 Hz, 1.2 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.6 Hz, 3H), 7.10-7.06 (m, 2H), 6.50 (d, J = 15.8 Hz, 1H), 6.39 (dt, J = 16.0 Hz, 6.8 Hz, 1H), 3.56 (d, J = 6.8 Hz, 2H), 2.38 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 140.1, 138.1, 137.1, 131.0, 129.4, 129.3, 128.5, 128.4, 127.1, 126.9, 126.1, 125.7, 39.3, 21.4; EI-MS (m/z): 208.1. The spectroscopic data for this product match the literature data.^[9]



1-Cinnamyl-2,4-dimethylbenzene (**4bd**). (39.1 mg, 88%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, J = 7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 7.24-7.20 (m, 1H), 7.12 (d, J = 7.6 Hz, 1H), 7.03-6.99 (m, 2H), 6.43-6.36 (m, 2H), 3.53 (d, J = 5.2 Hz, 2H), 2.34 (s, 3H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 137.6, 136.2, 135.8, 135.1, 131.0, 130.7, 129.2, 128.8, 128.4, 127.0, 126.7, 126.0, 36.5, 20.9, 19.3; EI-MS (m/z): 222.1. The spectroscopic data for this product match the literature data.^[10]



5-Cinnamyl-2,3-dihydro-1H-indene (4be) and . (*E*)-5-(3-phenylprop-1-en-1-yl)-2,3-dihydro-1H-indene (4be') (combined 40.3 mg, 86%, 71:29). Isolated by preparative TLC (hexane, $R_f = 0.7$); Major and minor: ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.29 (m, 4H), 7.25-7.16 (m, 4H), 6.50 (d, *J* = 15.8 Hz, 1H), 6.39 (dt, *J* = 15.8, 6.6 Hz, 1H), 3.56 (d, *J* = 6.6 Hz, 2H), 2.94-2.90 (m, 4H), 2.13-2.09 (m, 2H); Major and minor: ¹³C NMR (125 MHz, CDCl₃) δ 144.7, 144.6, 143.4, 142.1, 140.5, 138.0, 137.6, 135.6, 131.4, 130.7, 129.8, 128.7, 128.5, 127.0, 126.5, 126.1, 124.8, 124.3, 122.0, 121.9, 39.4, 39.3, 32.8, 32.7, 32.6, 32.5, 25.6, 25.5; EI-MS (m/z): 234.1. The spectroscopic data for this product match the literature data.^[10]



1-Cinnamyl-4-methoxybenzene (4bf). (36.7 mg, 82%). Isolated by preparative TLC (hexane: ethyl acetate = 40:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.34 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.25-7.19 (m, 3H), 6.90 (d, J = 7.2 Hz, 2H), 6.47 (d, J = 15.8 Hz, 1H), 6.41-6.35 (m, 1H), 3.84 (s, 3H), 3.53 (d, J = 6.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 158.1, 137.6, 132.2, 130.8, 129.7, 129.6, 128.5, 127.2, 126.1, 113.9, 55.3, 38.5; EI-MS (m/z): 224.1. The spectroscopic data for this product match the literature data.^[9]



1-Cinnamyl-3-methoxybenzene (**4bg**). (36.3 mg, 81%). Isolated by preparative TLC (hexane: ethyl acetate =60:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.24 (m, 6H), 7.01-6.81 (m, 3H), 6.50 (d, J = 15.8 Hz, 1H), 6.40 (dt, J = 15.8, 6.8 Hz, 1H), 3.84 (s, 3H), 3.57 (d, J = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 159.8, 141.8, 137.5, 131.2, 129.5, 129.1, 128.5, 127.2, 126.2, 121.1, 114.4, 111.6, 55.2, 39.4; EI-MS (m/z): 224.1. The spectroscopic data for this product match the literature data.^[11]



5-Cinnamylbenzo[d][1,3]dioxole (4bh). (34.3 mg, 72%). Isolated by preparative TLC (hexane: ethyl acetate = 20:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.38 (d, J = 7.6 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.27-7.22 (m, 1H), 6.82-6.71 (m, 3H), 6.47 (d, J = 15.8 Hz, 1H), 6.35 (dt, J = 15.8, 6.7 Hz, 1H), 5.96 (s, 2H), 3.49 (d, J = 6.7 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 147.7, 145.9, 137.4, 133.9, 131.0, 129.3, 128.5, 127.1, 126.1, 121.4, 109.2, 108.2, 100.8, 39.0; EI-MS (m/z): 238.1. The spectroscopic data for this product match the literature data.^[12]



5-Cinnamyl-1,2,3-trimethoxybenzene (4bi). (44.3 mg, 78%). Isolated by preparative TLC (hexane: ethyl acetate = 8:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.40 (d, J = 8.0 Hz, 2H), 7.34-7.31 (m, 2H), 7.25-7.21 (m, 1H), 6.50 (d, J = 15.6 Hz, 1H), 6.49 (m, 2H), 6.41-6.34 (m, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.87 (s, 3H), 3.52 (d, J = 6.4 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 153.3, 137.4, 136.4, 135.9, 131.2, 129.0, 128.6, 127.2, 126.2, 105.6, 60.9, 56.1, 39.7; EI-MS (m/z): 284.1. The spectroscopic data for this product match the literature data.^[13]



1-Cinnamyl-2-fluorobenzene (4bj). (39.4 mg, 93%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 7.42-7.22 (m, 7H), 7.15-7.04 (m, 2H), 6.51 (d, J = 15.8 Hz, 1H), 6.39 (dt, J = 15.8, 6.6 Hz, 1H), 3.62 (d, J = 6.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 161.0 (d, $J_{C-F} = 244.2$ Hz), 137.3, 131.4, 130.6 (d, $J_{C-F} = 4.8$ Hz), 128.5, 127.9 (d, $J_{C-F} = 8.4$ Hz), 127.6, 127.2, 127.1 (d, $J_{C-F} = 16.7$ Hz), 126.1, 32.2 (d, $J_{C-F} = 3.3$ Hz), 124.1 (d, $J_{C-F} = 3.6$ Hz), 115.3 (d, $J_{C-F} = 21.5$ Hz), 32.3; ¹⁹F NMR (470 MHz, CDCl₃) δ -118.4; EI-MS (m/z): 212.1. The spectroscopic data for this product match the literature data.^[14]



1-Cinnamyl-4-fluorobenzene (4bk). (40.7 mg, 96%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.22 (m, 7H), 7.06-7.01 (m, 2H), 6.48 (d, J = 15.6 Hz, 1H), 6.36 (dt, J = 15.6, 6.8 Hz,

1H), 3.56 (d, J = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 161.5 (d, $J_{C-F} = 243.3$ Hz), 137.4, 135.8 (d, $J_{C-F} = 3.9$ Hz), 131.3, 130.0 (d, $J_{C-F} = 7.7$ Hz), 129.0, 128.6, 127.3, 126.2, 115.3 (d, $J_{C-F} = 21.0$ Hz), 38.5; ¹⁹F NMR (470 MHz, CDCl₃) δ -117.2; EI-MS (m/z): 212.1. The spectroscopic data for this product match the literature data.^[1]



2-Cinnamylnaphthalene (4bl). (37.1 mg, 76%). Isolated by preparative TLC (hexane, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.86-7.84 (m, 3H), 7.72 (s, 1H), 7.50-7.45 (m, 2H), 7.42-7.40 (m, 3H), 7.32 (t, J = 7.5 Hz, 2H), 7.24 (t, J = 7.3 Hz, 1H), 6.54 (d, J = 15.8 Hz, 1H), 6.47 (dt, J = 15.8, 6.2 Hz, 1H), 3.75 (d, J = 6.2 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 137.7, 137.5, 133.7, 132.2, 131.3, 129.1, 128.5, 128.0, 127.6, 127.5, 127.4, 127.1, 126.7, 126.2, 126.0, 125.3, 39.5; EI-MS (m/z): 244.1. The spectroscopic data for this product match the literature data.^[12]



1-Cinnamylnaphthalene (4bm). (31.7 mg, 65%). Isolated by preparative TLC (hexane, $R_f = 0.7$); ¹H NMR (500 MHz, CDCl₃) δ 8.19-8.13 (m, 1H), 7.93-7.88 (m, 1H), 7.82-7.79 (m, 1H), 7.58-7.22 (m, 9H), 6.59-6.41 (m, 2H), 4.05 (d, J = 4.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 137.5, 136.3, 133.9, 132.1, 131.3, 128.9, 128.7, 128.5, 127.1, 126.4, 126.1, 125.9, 125.6, 125.5, 124.0, 36.5; EI-MS (m/z): 244.1. The spectroscopic data for this product match the literature data.^[14]



(*E*)-2-(3-(4-Methoxyphenyl)allyl)furan (4bn). (29.1 mg, 68%). Isolated by preparative TLC (hexane: ethyl acetate = 60:1, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.37 (dd, J = 0.8, 1.8 Hz, 1H), 7.33 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.47 (d, J = 15.7 Hz, 1H), 6.33 (dd, J = 1.9, 3.1 Hz, 1H), 6.19 (dt, J = 15.7, 6.8 Hz, 1H), 6.09 (dd, J = 0.8, 3.1 Hz, 1H), 3.83 (s, 3H), 3.56 (d, J = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 159.0, 154.2, 141.3, 131.4, 130.1, 127.3, 123.4, 113.9, 110.3, 105.5, 55.3, 31.8; EI-MS (m/z): 214.1. The spectroscopic data for this product match the literature data.^[15]



(*E*)-3-(3-(4-Methoxyphenyl)allyl)thiophene (4bn) and (*E*)-3-(3-(4-Methoxyphenyl)prop-1-en-1-yl) thiophene (4bn'). (combined 17.5 mg, 38%, 40:60). Isolated by preparative TLC (hexane: ethyl acetate = 60:1, R_f = 0.5); Major and minor: ¹H NMR (500 MHz, CDCl₃) δ 7.33-7.31 (m, 1H), 7.31-7.29 (m, 1H), 7.27-7.26 (m, 1H), 7.04-7.02 (m, 1H), 7.02-6.99 (m, 1H), 6.91-6.90 (m, 1H), 6.88-6.86 (m, 1H), 6.54 (d, *J* =11.4 Hz, 0.6H), 6.43 (d, *J* =15.8 Hz, 0.4H), 6.25 (dt, *J* =15.8, 6.8 Hz, 0.4H), 5.83 (dt, *J* =11.4, 7.4 Hz, 0.6H), 3.84 (s, 1.8 H), 3.83 (s, 1.2 H), 3.68 (d, *J* = 7.4 Hz, 1.2H), 3.56 (d, *J* = 6.8 Hz, 0.8H); Major and minor: ¹³C NMR (125 MHz, CDCl₃) δ 158.9,

158.5, 141.1, 140.9, 130.4, 130.3, 129.9, 129.8, 129.5, 128.5, 128.4, 128.2, 127.2, 126.4, 125.6, 125.5, 120.8, 120.4, 114.0, 113.7, 55.3, 33.8, 29.5; EI-MS (m/z): 230.1. The spectroscopic data for this product match the literature data.^[15,16]



(*E*)-1-Methoxy-4-(pent-1-en-1-yl)benzene (4bp). (14.8 mg, 42%). Isolated by preparative TLC (hexane: ethyl acetate = 150:1, $R_f = 0.6$); ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, *J* = 8.8 Hz, 2H), 6.86 (d, *J* = 8.8 Hz, 2H), 6.34 (d, *J* = 15.8 Hz, 1H), 6.10 (dt, *J* = 15.8, 6.8 Hz, 1H), 3.82 (s, 3H), 2.19 (ddd, *J* = 15.8, 7.0, 1.3 Hz, 2H), 1.50 (dq, *J* = 14.5, 7.2 Hz, 2H), 0.97 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 158.6, 130.8, 129.2, 128.9, 127.0, 113.9, 55.3, 35.1, 22.7, 13.7; EI-MS (m/z): 176.1. The spectroscopic data for this product match the literature data.^[16]



(*E*)-1-Methoxy-4-(4-methylpent-1-en-1-yl)benzene (4bq). (14.8 mg, 39%). Isolated by preparative TLC (hexane: ethyl acetate =100:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.30 (t, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.33 (d, J = 15.7 Hz, 1H), 6.10 (dt, J = 15.7, 7.2 Hz, 1H), 3.83 (s, 3H), 2.10 (td, J = 7.2, 1.3 Hz, 2H), 1.77-1.69 (m, 1H), 0.96 (d, J = 6.6 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 158.6, 130.8, 130.1, 127.7, 127.0, 113.9, 55.3, 42.4, 28.7, 22.4; EI-MS (m/z): 190.1. The spectroscopic data for this product match the literature data.^[17]



(*E*)-1-(2-Cyclohexylvinyl)-4-methoxybenzene (4br). (17.3 mg, 40%). Isolated by preparative TLC (hexane: ethyl acetate =80:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.31 (d, J = 16.0 Hz, 1H), 6.06 (dd, J = 16.0, 7.0 Hz, 1H), 3.82 (s, 3H), 2.15-2.09 (m, 1H), 1.85-1.68 (m, 5H), 1.36-1.18 (m, 5H); ¹³C NMR (125 MHz, CDCl₃) δ 158.6, 134.8, 130.9, 127.0, 126.5, 113.9, 55.3, 41.1, 33.1, 26.2, 26.1; EI-MS (m/z): 216.2. The spectroscopic data for this product match the literature data.^[18]



1-Cinnamyl-2-methoxybenzene (**4ca**). (41.2 mg, 92%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.40-7.38 (m, 2H), 7.33-7.30 (m, 2H), 7.27-7.21 (m, 3H), 6.95 (td, *J* = 7.4, 1.0 Hz, 1H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.48 (d, *J* = 16.0 Hz, 1H), 6.45-6.40 (m, 1H), 3.89 (s, 3H), 3.58 (d, *J* = 6.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 137.8, 130.7, 130.0, 128.9, 128.7, 128.5, 127.4, 126.9, 126.1, 120.6, 110.4, 55.4, 33.4; EI-MS (m/z): 224.1. The spectroscopic data for this product match the literature data.^[19]



(*E*)-1-Methoxy-2-(3-(p-tolyl)allyl)benzene (4cb). (40.5 mg, 85%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.31 (d, *J* = 8.0 Hz, 2H), 7.26-7.17 (m, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 6.97 (t, *J* = 7.2 Hz, 1H), 6.93 (d, *J* = 7.2 Hz, 1H), 6.47 (d, *J* = 15.8 Hz, 1H), 6.43-6.36 (m, 1H), 3.90 (s, 3H), 3.59 (d, *J* = 6.5 Hz, 2H), 2.38 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 136.6, 135.0, 130.6, 129.9, 129.2, 127.9, 127.4, 126.0, 120.6, 110.4, 55.4, 33.4, 21.2; HRMS (ESI) calcd for C₁₇H₁₉O [M + H⁺], 239.1430; found: 239.1426.



(*E*)-1-Methoxy-2-(3-(m-tolyl)allyl)benzene (4cc). (37.2 mg, 78%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.20 (m, 5H), 7.06-7.04 (m, 1H), 6.95 (td, *J* = 7.4, 1.0 Hz, 1H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.45 (d, *J* = 15.8 Hz, 1H), 6.44-6.37 (m, 1H), 3.89 (s, 3H), 3.58 (d, *J* = 5.6 Hz, 2H), 2.37 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 138.0, 137.7, 130.8, 129.9, 128.8, 128.7, 128.4, 127.7, 127.4, 126.8, 123.3, 120.6, 110.4, 55.4, 33.4, 21.4; HRMS (ESI) calcd for C₁₇H₁₉O [M + H⁺], 239.1430; found: 239.1431.



(*E*)-1-(3-(4-Fluorophenyl)allyl)-2-methoxybenzene (4cd). (46.5 mg, 83%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.34 (m, 4H), 7.27-7.24 (m, 2H), 6.96 (td, *J* = 7.4, 1.0 Hz, 1H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.48 (d, *J* = 15.8 Hz, 1H), 6.43-6.37 (m, 1H), 3.89 (s, 3H), 3.59 (d, *J* = 6.7 Hz, 2H), 1.36 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 149.9, 135.1, 130.5, 129.8, 128.9, 128.1, 127.4, 125.8, 125.4, 120.5, 110.4, 55.4, 34.5, 33.4, 31.4; HRMS (ESI) calcd for C₂₀H₂₅O [M + H⁺], 281.1900; found: 281.1902.



(*E*)-1-Methoxy-2-(3-(4-methoxyphenyl)allyl)benzene (4ce).^[17] (41.7 mg, 82%). Isolated by preparative TLC (hexane: ethyl acetate = 40:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.32 (d, *J* = 8.8 Hz, 2H), 7.26-7.20 (m, 2H), 6.94 (td, *J* = 7.4, 1.0 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 6.86 (d, *J* = 8.8 Hz, 2H), 6.41 (d, *J* = 15.8 Hz, 1H),

6.30-6.25 (m, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.55 (d, J = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 158.7, 157.3, 130.7, 130.1, 129.8, 129.6, 129.0, 127.3, 127.2, 126.7, 120.5, 113.9, 110.4, 55.4, 55.3, 33.3; EI-MS (m/z): 254.1.



(*E*)-1,2-Dimethoxy-4-(3-(2-methoxyphenyl)prop-1-en-1-yl)benzene (4cf). (51.7 mg, 91%). Isolated by preparative TLC (hexane: ethyl acetate = 8:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.23 (m, 2H), 7.00-6.89 (m, 4H), 6.84-6.81 (m, 1H), 6.41 (d, *J* = 15.8 Hz, 1H), 6.30-6.25 (m, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.88 (s, 3H), 3.57 (d, *J* = 6.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 149.0, 148.3, 131.0, 130.3, 129.9, 128.9, 127.4, 127.0, 120.5, 119.0, 111.1, 110.4, 108.7, 55.9, 55.8, 55.4, 33.3; HRMS (ESI) calcd for C₁₈H₂₁O₃ [M + H⁺], 285.1485; found: 285.1481.



(*E*)-2-(3-(2-Methoxyphenyl)prop-1-en-1-yl)-1,4-dimethylbenzene (4cg). (43.9 mg, 87%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.30-7.05 (m, 4H), 7.03-6.89 (m, 3H), 6.68 (d, *J* = 15.8 Hz, 1H), 6.39-6.25 (m, 1H), 3.90 (s, 3H), 3.61 (d, *J* = 6.8 Hz, 2H), 2.34 (s, 3H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 136.7, 135.3, 132.0, 130.1, 129.8, 129.7, 128.9, 128.8, 127.6, 127.4, 126.2, 120.6, 110.3, 55.4, 33.7, 21.0, 19.4; HRMS (ESI) calcd for C₁₈H₂₁O [M + H⁺], 253.1587; found: 253.1590.



(*E*)-4-(3-(2-Methoxyphenyl)prop-1-en-1-yl)-1,1'-biphenyl (4ch). (49.2 mg, 82%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.64-7.62 (m, 2H), 7.59-7.55 (m, 2H), 7.48-7.45 (m, 4H), 7.38-7.34 (m, 1H), 7.28-7.22 (m, 2H), 6.96 (td, *J* = 7.4, 1.0 Hz, 1H), 6.92 (d, *J* = 8.0 Hz, 1H), 6.52 (d, *J* = 15.8 Hz, 1H), 6.49-6.39 (m, 1H), 3.90 (s, 3H), 3.60 (d, *J* = 5.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 140.9, 139.7, 136.9, 130.2, 129.9, 129.2, 128.8, 127.5, 127.2, 126.9, 126.5, 120.6, 110.4, 55.4, 33.5; HRMS (ESI) calcd for C₂₂H₂₁O [M + H⁺], 301.1587; found: 301.1585.



(*E*)-1-(3-(4-Fluorophenyl)allyl)-2-methoxybenzene (4ci). (39.7 mg, 81%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.33 (m, 2H), 7.28-7.22 (m, 2H), 7.05-6.98 (m, 2H), 6.96 (td, *J* = 7.4, 1.0 Hz, 1H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.39-6.31 (m, 1H), 3.89 (s, 3H), 3.57 (d, *J* = 6.5 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 162.0 (d, *J*_{C-F} = 245.8 Hz), 157.3, 134.0 (d, *J*_{C-F} = 3.2 Hz), 129.9, 129.5, 128.7, 128.6, 127.6 (d, *J*_{C-F} = 7.6 Hz), 127.5, 120.6, 115.3 (d, *J*_{C-F} = 21.8 Hz), 110.4, 55.4, 33.4; ¹⁹F NMR (470 MHz, CDCl₃) δ -115.7; HRMS (ESI) calcd for C₁₆H₁₆FO [M + H⁺], 243.1180; found: 243.1182.



(*E*)-4-(3-(2-methoxyphenyl)prop-1-en-1-yl)aniline (4cj). (36.8 mg, 77%). Isolated by preparative TLC (hexane: ethyl acetate = 2:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.26-7.19 (m, 4H), 6.94 (td, *J* = 7.4, 1.0 Hz, 1H), 6.91 (dd, *J* = 8.4, 0.8 Hz, 1H), 6.64 (d, *J* = 8.6 Hz, 2H), 6.38 (d, *J* = 15.8 Hz, 1H), 6.25-6.19 (m, 1H), 3.88 (s, 3H), 3.65 (br, 2H), 3.54 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 145.4, 130.5, 129.8, 129.2, 128.7, 127.3, 127.2, 125.2, 120.5, 115.2, 110.4, 55.4, 33.3; HRMS (ESI) calcd for C₁₆H₁₈NO [M + H⁺], 240.1383; found: 240.1385.



(*E*)-4-(3-(2-Methoxyphenyl)prop-1-en-1-yl)phenol (4ck). (25.5 mg, 53%). Isolated by preparative TLC (hexane: ethyl acetate = 5:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.25 (m, 2H), 7.23-7.21 (m, 2H), 6.95-6.88 (m, 2H), 6.80-6.76 (m, 2H), 6.39 (d, *J* = 15.8 Hz, 1H), 6.28-6.22 (m, 1H), 4.85 (br, 1H), 3.87 (s, 3H), 3.54 (d, *J* = 6.7 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 154.6, 130.8, 130.0, 129.8, 128.9, 127.4, 127.3, 126.8, 120.5, 115.3, 110.4, 55.4, 33.3; HRMS (ESI) calcd for C₁₆H₁₇O₂ [M + H⁺], 241.1223; found: 241.1225.



(*E*)-4-(3-(2-Methoxyphenyl)prop-1-en-1-yl)phenyl acetate (4cl). (21.4 mg, 38%). Isolated by preparative TLC (hexane: ethyl acetate = 10:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, *J* = 8.6 Hz, 2H), 7.24 (td, *J* = 7.8, 1.7 Hz, 1H), 7.21 (td, *J* = 7.4, 1.7 Hz, 1H), 7.02 (d, *J* = 8.6 Hz, 2H), 6.94 (td, *J* = 7.4, 1.0 Hz, 1H), 6.90 (d, *J* = 8.2 Hz, 1H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.38-6.33 (m, 1H), 3.87 (s, 3H), 3.55 (d, *J* = 6.5 Hz, 2H), 2.31 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.5, 157.3, 149.5, 135.6, 129.8, 129.7, 129.3, 128.6, 127.5, 127.0, 121.5, 120.6, 110.4, 55.4, 33.4, 21.1; HRMS (ESI) calcd for C₁₈H₁₉O₃ [M + H⁺], 283.1329; found: 283.1333.



(*E*)-2-(3-(2-methoxyphenyl)prop-1-en-1-yl)naphthalene (4cm). (41.2 mg, 75%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.86-7.82 (m, 2H), 7.80 (d, *J* = 7.6 Hz, 1H), 7.74 (s, 1H), 7.65 (dd, *J* = 8.6, 1.7 Hz, 1H), 7.51-7.44 (m, 2H), 7.30-7.27 (m, 2H), 6.99 (td, *J* = 7.6, 1.0 Hz, 1H), 6.95 (dd, *J* = 8.6, 1.0 Hz, 1H), 6.66 (d, *J* = 15.8 Hz, 1H), 6.61-6.55 (m, 1H), 3.92 (s, 3H), 3.67 (d, *J* = 6.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.4, 135.3, 133.7, 132.7, 130.8, 130.0, 129.5, 128.7, 128.0, 127.9, 127.7, 127.5, 126.1, 125.6, 125.5, 123.7, 120.6, 110.5, 55.5, 33.6; HRMS (ESI) calcd for C₂₀H₁₉O [M + H⁺], 275.1430; found: 275.1428.



(*E*)-2-(3-(2-methoxyphenyl)prop-1-en-1-yl)pyridine (4cn). (37.2 mg, 83%). Isolated by preparative TLC (hexane: ethyl acetate = 5:1, $R_f = 0.5$); ¹H NMR (400 MHz, CDCl₃) δ 8.54 (d, *J* = 4.2 Hz, 1H), 7.60 (td, *J* = 7.8, 1.8 Hz, 1H), 7.28 (d, *J* = 7.8 Hz, 1H), 7.25-7.21 (m, 2H), 7.11-7.08 (m, 1H), 6.95-6.87 (m, 3H), 6.54 (dt, *J* = 15.8, 1.4 Hz, 1H), 3.87 (s, 3H), 3.62 (dd, *J* = 6.8, 0.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 156.1, 149.3, 136.4, 134.0, 130.6, 130.1, 128.0, 127.6, 121.6, 121.0, 120.6, 110.4, 55.4, 33.4; HRMS (APCI) calcd for C₁₅H₁₆ON [M + H+], 226.1226; found: 226.1229.



(*E*)-5-(3-(2-Methoxyphenyl)prop-1-en-1-yl)-1-methyl-1H-indole (4co). (39.4 mg, 71%). Isolated by preparative TLC (hexane: ethyl acetate = 20:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.63 (s, 1H), 7.37 (dd, *J* = 8.6, 1.5 Hz, 1H), 7.30-7.24 (m, 3H), 7.04 (d, *J* = 3.0 Hz, 1H), 6.97 (td, *J* = 7.4, 0.9 Hz, 1H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.62 (d, *J* = 15.8 Hz, 1H), 6.48 (dd, *J* = 3.0, 0.6 Hz, 1H), 6.38 (dt, *J* = 15.8, 6.8 Hz, 1H), 3.91 (s, 3H), 3.80 (s, 3H), 3.62 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.4, 136.2, 131.9, 129.9, 129.5, 129.4, 129.1, 128.7, 127.3, 125.8, 120.6, 120.0, 118.9, 110.4, 109.2, 101.1, 55.5, 33.4, 32.9; HRMS (APCI) calcd for C₁₉H₂₀ON [M + H⁺], 278.1539; found: 278.1548.



(*E*)-1-(4-(3-(2-methoxyphenyl)prop-1-en-1-yl)benzyl)-1H-indole (4cp). (57.1 mg, 81%). Isolated by preparative TLC (hexane: ethyl acetate = 10:1, $R_f = 0.5$); ¹H NMR (400 MHz, CDCl₃) δ 7.76-7.74 (m, 1H), 7.40-7.38 (m, 1H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.32-7.26 (m, 3H), 7.23-7.18 (m, 2H), 7.10 (d, *J* = 8.2 Hz, 2H), 7.00 (td, *J* = 7.4, 1.0 Hz, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 6.65-6.63 (m, 1H), 6.49 (d, *J* = 15.8 Hz, 1H), 6.46-6.38 (m, 1H), 5.33 (s, 2H), 3.91 (s, 3H), 3.62 (d, *J* = 5.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 157.4, 137.3, 136.1, 130.2, 129.9, 129.3, 129.1, 128.8, 128.6, 128.3, 127.5, 127.1, 126.5, 121.7, 121.0, 120.6, 119.6, 110.5, 109.8, 101.7, 55.4, 49.9, 33.5; HRMS (APCI) calcd for C₂₅H₂₄ON [M + H⁺], 354.1852; found: 354.1856.



(*E*)-2-(3-(2-Methoxyphenyl)prop-1-en-1-yl)dibenzo[b,d]furan (4cq). (39.4 mg, 92%). Isolated by preparative TLC (hexane: ethyl acetate =60:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.98-7.96 (m, 2H), 7.61-7.59 (m, 1H), 7.56-7.47 (m, 3H), 7.41-7.36 (m, 1H), 7.30-7.26 (m, 2H), 7.01-6.92 (m, 2H), 6.64 (d, *J* = 15.8 Hz, 1H), 6.51-6.46 (m, 1H), 3.92 (s, 3H), 3.65 (d, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.4, 156.6, 155.5, 133.0, 130.5, 130.0, 128.8, 128.3, 127.5, 127.1, 125.6, 124.5, 124.3, 122.7, 120.7, 120.6, 118.0, 111.7, 111.5, 110.5, 55.5, 33.5; HRMS (APCI) calcd for C₂₂H₁₉O₂ [M + H⁺], 315.1380; found: 315.1382.



(*E*)-9-Ethyl-3-(3-(2-methoxyphenyl)prop-1-en-1-yl)-9H-carbazole (4cr). (46.4 mg, 68%). Isolated by preparative TLC (hexane: ethyl acetate = 10:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 8.13-8.11 (m, 2H), 7.57 (dd, J = 8.4, 1.6 Hz, 1H), 7.49 (td, J = 7.6, 1.2 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.32 (dd, J = 8.6, 1.6 Hz, 1H), 7.27-7.24 (m, 2H), 6.98 (td, J = 7.4, 0.9 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.68 (d, J = 15.8 Hz, 1H), 6.45 (dt, J = 15.8, 6.8 Hz, 1H), 4.38 (q, J = 7.2 Hz, 2H), 3.92 (s, 3H), 3.65 (d, J = 6.8 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.4, 140.3, 139.3, 131.4, 129.9, 129.2, 129.1, 127.3, 126.1, 125.6, 124.1, 123.1, 123.0, 120.6, 120.5, 118.8, 118.1, 110.4, 108.5, 108.4, 55.5, 37.6, 33.5, 13.8; HRMS (APCI) calcd for C₂₄H₂₄ON [M + H⁺], 342.1852; found: 342.1862.



(*E*)-4-methoxy-9-(4-(3-(2-methoxyphenyl)prop-1-en-1-yl)benzyl)-9H-carbazole (4cs). (76.2 mg, 88%). Isolated by preparative TLC (hexane: ethyl acetate = 10:1, $R_f = 0.6$); ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, *J* = 7.6 Hz, 1H), 7.47-7.38 (m, 3H), 7.36-7.32 (m, 1H), 7.30-7.26 (m, 3H), 7.24-7.11 (m, 2H), 7.09 (d, *J* = 8.2 Hz, 2H), 6.96 (td, *J* = 7.4, 0.9 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 1H), 6.76 (d, *J* = 8.0 Hz, 1H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.40-6.33 (m, 1H), 5.49 (s, 2H), 4.15 (s, 3H), 3.88 (s, 3H), 3.57 (d, *J* = 5.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 156.4, 142.2, 139.9, 137.1, 135.9, 130.2, 129.9, 129.1, 128.6, 127.5, 126.7, 126.6, 126.5, 124.9, 123.2, 122.5, 120.6, 119.5, 112.2, 110.4, 108.4, 102.0, 100.4, 55.5, 55.4, 46.6, 33.4; HRMS (APCI) calcd for C₃₀H₂₈O₂N [M + H⁺], 434.2115; found: 434.2110.



1-((*E*)-3-(4-((((1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl)oxy)methyl)phenyl)allyl)-2-methoxybenzene (6). (0.1 mmol scale, 31 mg, 79%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.35 (d, *J* = 8.2 Hz, 2H), 7.29 (d, *J* = 8.2 Hz, 2H), 7.27-7.22 (m, 2H), 6.94 (t, *J* = 7.1 Hz, 1H), 6.91 (d, *J* = 8.2 Hz, 1H), 6.45 (d, *J* = 15.8 Hz, 1H), 6.40 (td, *J* = 15.8, 6.0 Hz, 1H), 4.65 (d, *J* = 11.6 Hz, 1H), 4.40 (d, *J* = 11.6 Hz, 1H), 3.88 (s, 3H), 3.57 (d, *J* = 6.2 Hz, 2H), 3.23-3.16 (m, 1H), 2.35-2.30 (m, 1H), 2.25-2.20 (m, 1H), 1.70-1.63 (m, 2H), 1.42-1.29 (m, 2H), 1.03-0.85 (m, 9H), 0.74 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 137.8, 137.0, 130.5, 129.9, 128.7, 128.1, 128.0, 127.4, 126.0, 120.6, 110.4, 78.6, 70.2, 55.4, 48.4, 40.3, 34.6, 33.4, 31.6, 25.5, 23.3, 22.4, 21.1, 16.1; HRMS (ESI) calcd for C₄₆H₆₇O₃ [M + H⁺], 415.2608; found: 415.2603.



(*E*)-1-(4-(3-(2-Methoxyphenyl)prop-1-en-1-yl)benzyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione (8). (0.1 mmol scale, 38.3 mg, 92%). Isolated by preparative TLC (dichloromethane: methanol = 1:10, $R_f = 0.3$); ¹H NMR (500 MHz, CDCl₃) δ 7.50 (s, 1H), 7.44 (d, *J* = 8.2 Hz, 2H), 7.31 (d, *J* = 8.2 Hz, 2H), 7.24-7.17 (m, 2H), 6.93-6.86 (m, 2H), 6.41 (d, J = 15.8 Hz, 1H), 6.35 (td, J = 15.8, 6.4 Hz, 1H), 5.17 (s, 2H), 3.99 (s, 3H), 3.85 (s, 3H), 3.59 (s, 3H), 3.53 (d, J = 6.4 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 155.3, 151.6, 148.9, 141.5, 137.2, 136.0, 130.4, 129.8, 129.1, 129.0, 128.7, 127.4, 126.1, 120.5, 110.3, 107.7, 55.4, 44.2, 33.6, 33.4, 29.8; HRMS (ESI) calcd for C₂₄H₂₅O₃N₄ [M + H⁺], 417.1921; found: 417.1920.



(*E*)-7-(4-(3-(2-methoxyphenyl)prop-1-en-1-yl)benzyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (10). (37.2 mg, 88%). Isolated by preparative TLC (dichloromethane: methanol = 1:10, $R_f = 0.4$); ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 2H), 7.23-7.17 (m, 2H), 6.94-6.88 (m, 2H), 6.40 (s, 2H), 5.50-5.47 (m, 2H), 3.86 (m, 3H), 3.60 (s, 3H), 3.55 (s, 2H), 3.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 155.3, 151.7, 148.9, 140.8, 138.3, 133.6, 130.1, 129.8, 129.7, 128.4, 128.2, 127.5, 126.9, 126.7, 120.5, 110.4, 55.4, 50.1, 33.4, 29.8, 28.0; HRMS (APCI) calcd for C₂₄H₂₅O₃N₄ [M + H⁺], 417.1921; found: 417.1916.



(8R,9S,13S,14S)-3-((*E*)-3-(2-Methoxyphenyl)prop-1-en-1-yl)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro -17H-cyclopenta[a]phenanthren-17-one (12). (0.1 mmol scale, 36.4 mg, 91%). Isolated by preparative TLC (hexane: ethyl acetate =5:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.26-7.19 (m, 4H), 7.13 (s, 1H), 6.96-6.90 (m, 2H), 6.44-6.34 (m, 2H), 3.88 (s, 3H), 3.57 (d, *J* = 6.2 Hz, 2H), 2.94-2.91 (m, 2H), 2.57-2.51 (m, 1H), 2.46-2.43 (m, 1H), 2.33-2.30 (m, 1H), 2.21-2.14 (m, 1H), 2.11-1.98 (m, 3H), 1.70-1.57 (m, 3H), 1.55-1.45 (m, 3H), 0.94 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 220.9, 157.3, 138.6, 136.5, 135.4, 130.4, 129.8, 128.8, 128.3, 127.4, 126.7, 125.5, 123.6, 120.5, 110.4, 55.4, 50.5, 48.0, 44.4, 38.2, 35.9, 33.4, 31.6, 29.4, 26.6, 25.8, 21.6, 13.9; HRMS (APCI) calcd for C₂₈H₃₃O₂ [M + H⁺], 401.2475; found: 401.2484.



(8R,9S,13S,14S)-3-((4-((*E*)-3-(2-Methoxyphenyl)prop-1-en-1-yl)benzyl)oxy)-13-methyl-6,7,8,9,11,12,13,14,1 5,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (14). (0.1 mmol scale, 38.5 mg, 76%). Isolated by preparative TLC (hexane: ethyl acetate =5:1, $R_f = 0.5$); ¹H NMR (500 MHz, CDCl₃) δ 7.44-7.35 (m, 4H), 7.26-7.21 (m, 3H), 6.96-6.89 (m, 2H), 6.84-6.74 (m, 2H), 6.48-6.38 (m, 2H), 5.04 (s, 2H), 3.88 (s, 3H), 3.57 (d, *J* = 5.7 Hz, 2H), 2.94-2.90 (m, 2H), 2.56-2.50 (m, 1H), 2.44-2.40 (m, 1H), 2.30-2.26 (m, 1H), 2.21-2.13 (m, 1H), 2.11-1.97 (m, 3H), 1.69-1.61 (m, 3H), 1.55-1.46 (m, 3H), 0.94 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 221.0, 157.3, 156.9, 137.8, 137.5, 135.8, 132.3, 130.3, 129.9, 129.2, 128.6, 127.6, 127.5, 126.3, 126.2, 120.6, 115.0, 112.5, 110.4, 69.8, 55.4, 50.4, 48.0, 44.0, 38.4, 35.9, 33.4, 31.6, 29.7, 26.6, 25.9, 21.6, 13.9; HRMS (APCI) calcd for C₃₅H₃₉O₃ [M + H⁺], 507.2907; found: 507.2894.



Ethyl (*S*,*E*)-2-acetamido-3-(4-((4-(3-(2-methoxyphenyl)prop-1-en-1-yl)benzyl)oxy)phenyl)propanoate (16). (0.1 mmol scale, 30.2 mg, 62%). Isolated by preparative TLC (hexane: ethyl acetate = 1:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.38 (d, *J* = 8.2 Hz, 2H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.26-7.20 (m, 2H), 7.05-7.02 (m, 2H), 6.95-6.89 (m, 4H), 6.48-6.38 (m, 2H), 5.94 (d, *J* = 7.4 Hz, 1H), 5.02 (s, 2H), 4.87-4.82 (m, 1H), 4.22-4.17 (m, 2H), 3.87 (s, 3H), 3.57 (d, *J* = 5.6 Hz, 2H), 3.12-3.05 (m, 2H), 2.01 (s, 3H), 1.27 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 171.7, 169.6, 157.9, 157.3, 137.6, 135.5, 130.3, 130.2, 129.9, 129.3, 129.0, 128.6, 128.1, 127.7, 127.5, 126.3, 120.6, 115.0, 110.4, 69.9, 61.5, 55.4, 53.3, 37.1, 33.4, 23.2, 14.2; HRMS (APCI) calcd for C₃₀H₃₄O₅N [M + H⁺], 488.2432; found: 488.2437.



(**R**)-6-((4-((*E*)-3-(2-Methoxyphenyl)prop-1-en-1-yl)benzyl)oxy)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trime thyltridecyl)chromane (18). (0.1 mmol scale, 55.3 mg, 83%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, R_f = 0.5); ¹H NMR (500 MHz, CDCl₃) δ 7.47 (d, *J* = 8.2 Hz, 2H), 7.44 (d, *J* = 8.2 Hz, 2H), 7.29-7.26 (m, 2H), 6.98 (td, *J* = 7.6, 0.8 Hz, 1H), 6.94 (d, *J* = 8.2 Hz, 1H), 6.52 (d, *J* = 15.8 Hz, 1H), 6.46 (td, *J* = 15.8, 6.0 Hz, 1H), 4.73 (s, 2H), 3.91 (s, 3H), 3.62 (d, *J* = 6.0 Hz, 2H), 2.65 (t, *J* = 6.6 Hz, 2H), 2.27 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H),

1.92-1.80 (m, 2H), 1.66-1.55 (m, 3H), 1.52-1.44 (m, 4H), 1.38-1.28 (m, 11H), 1.23-1.11 (m, 6H), 0.95-1.91 (m, 12H); 13 C NMR (125 MHz, CDCl₃) δ 157.4, 148.2, 147.9, 137.4, 136.7, 130.5, 129.9, 129.0, 128.7, 127.9, 127.5, 126.2, 126.0, 122.9, 120.6, 117.6, 110.4, 74.8, 74.6, 55.4, 40.1, 39.4, 37.5, 37.4, 33.5, 32.8, 32.7, 31.4, 28.0, 24.9, 24.5, 24.0, 22.8, 22.7, 21.1, 20.7, 19.8, 19.7, 13.0, 12.1, 11.9; HRMS (APCI) calcd for C₄₆H₆₇O₃ [M + H⁺], 667.5085; found: 667.5104.



(3S,8R,9S,10S,13R,14S,17R)-3-((3-((*E*)-3-(2-Methoxyphenyl)prop-1-en-1-yl)benzyl)oxy)-10,13-dimethyl-17 -((R)-6-methylheptan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthrene (20). (0.1 mmol scale, 53 mg, 85%). Isolated by preparative TLC (hexane: ethyl acetate = 50:1, $R_f = 0.4$); ¹H NMR (500 MHz, CDCl₃) δ 7.34 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.2 Hz, 2H), 7.26-7.21 (m, 2H), 6.94 (td, *J* = 7.4, 1.0 Hz, 1H), 6.90 (d, *J* = 8.0 Hz, 1H), 6.45 (d, *J* = 15.8 Hz, 1H), 6.39 (td, *J* = 15.8, 6.2 Hz, 1H), 4.57-4.51 (m, 2H), 3.88 (s, 3H), 3.56 (d, *J* = 6.2 Hz, 2H), 3.36-3.30 (m, 1H), 2.00-1.97 (m, 1H), 1.92-1.90 (m, 1H), 1.85-1.81 (m, 1H), 1.76-1.66 (m, 3H), 1.59-1.45 (m, 4H), 1.39-1.25 (m, 10H), 1.20-0.96 (m, 10H), 0.93 (d, *J* = 6.4 Hz, 3H), 0.90 (d, *J* = 2.2 Hz, 3H), 0.88 (s, 3H), 0.68 (s, 3H), 0.65-0.60 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 157.3, 137.9, 137.0, 130.5, 129.9, 128.7, 127.7, 127.4, 126.0, 120.5, 110.4, 77.8, 69.5, 56.5, 56.3, 55.4, 54.5, 44.9, 42.6, 40.1, 39.5, 37.0, 36.2, 35.8, 35.5, 34.9, 33.4, 32.2, 28.9, 28.3, 28.0, 24.2, 23.9, 22.8, 22.6, 21.3, 18.7, 12.3, 12.1; HRMS (APCI) calcd for C₄₄H₆₅O₂ [M + H⁺], 625.4979; found: 625.4982.

Mechanistic study

The phenyldiazomethane **21** was prepared following a literature procedure.^[20] To a solution of benzaldehyde **1a** (0.6 mmol) in THF (2.0 mL) was added hydrazine monohydrate (36 μ L, 0.72 mmol, 64–65 wt%). The resulting mixture was stirred for 30 min at room temperature and then cooled to 0 °C. Activated MnO₂ (2.4 mmol) and MgSO₄ (2.4 mmol) were added. The reaction mixture was stirred for 2 h at 0 °C and 1 h at room temperature, then filtered through celite and used immediately without further purification. When phenyldiazomethane was used instead of benzaldehyde hydrazone under the standard conditions, the desired product **4aa** was not observed (see Supplementary Figure 1a). This result excluded the participation of carbene or diazo compound species.

The 1,2-diphenylcyclopropane **22** was prepared following a literature procedure.^[21] A dry Schlenk was charged with styrene (2.0 mmol), K_2CO_3 (1.5 mmol), *N*-Tosyl phenylhydrazone (1.0 mmol) and dioxane (5.0 mL) under nitrogen atmosphere. The reaction mixture was heated at 110 °C, stirred and refluxed for 6 h. After the mixture was cooled to room temperature, diluted with dichloromethane (10.0 mL) and filtered through celite. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel with hexane to give the product **22** (*trans:cis* = 4.3:1). ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.31 (m, 4H), 7.23-7.20 (m, 2H), 7.18-7.16 (m, 4H), 7.13-7.10 (m, 0.92H), 7.08-7.05 (m, 0.46H), 6.98-6.96 (m, 0.92H), 2.51 (dd, *J* = 8.6, 6.4 Hz, 0.46H), 2.20 (dd, *J* = 7.4, 6.0 Hz, 2H), 1.50-1.46 (m, 2.46H). The spectroscopic data for this substrate match the literature data.^[21] When 1,2-diphenylcyclopropane **22** was used instead of benzaldehyde hydrazone and styrene under the standard conditions, the desired product **4aa** was not observed (see Supplementary Figure 1b). This result ruled out the pathway that ring opening of cyclopropane to give the desired product.

The 1-methoxy-4-(3-phenylpropyl)benzene **23** was prepared following a literature procedure.^[22] In a glovebox, a flame-dried reaction tube equipped with a magnetic stir bar was charged with Ni(cod)₂ (11.2 mg, 10 mol%), PMe₃ (17 µL, 40 mol%) and 1,4-dioxane (2.0 mL) before being sealed with a rubber septum and taken out of the glove box. The reaction mixture was stirred at room temperature for 30 min. Then 4-methoxyphenyl triflate (0.2 mmol), (3-bromopropyl)benzene (0.6 mmol), hydrazine solution (1 M in THF, 0.4 mmol, 400 µL) and K₃PO₄ (1.2 mmol) were added sequentially. After that, the reaction mixture was sealed with aluminum cap, moved out of glovebox and stirred at 110 °C for 12 h. After the mixture was cooled to room temperature, the resulting solution was directly filtered through a pad of silica and washed with EtOAc (5.0 mL). The solvent was evaporated *in vacuo* to give the crude product. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether) to give the pure substrate **23**. ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.30 (m, 2H), 7.23-7.20 (m, 3H), 7.14 (d, *J* = 8.6 Hz, 2H), 6.87 (d, *J* = 8.6 Hz, 2H), 3.83 (s, 3H), 2.68 (t, *J* = 7.6 Hz, 2H), 2.64 (t, *J* = 7.6 Hz, 2H), 2.00-1.94 (m, 2H). The spectroscopic data for this product match the literature data.^[22] When **23** was used under the standard conditions, the desired product **4aa** was not observed (see Supplementary Figure 1c). This result ruled out the hydrazone addition to the vinylarene and followed by dehydrogenation pathway.

When deuterated styrene (**3a**-D8) was reacted with hydrazone under the optimized conditions, the H/D exchanges both in the double bond moiety (73% D) and benzylic position (15% D) were observed in the corresponding product **4a**-D7. ¹H NMR (500 MHz, CDCl₃) δ 7.27-7.22 (m, 2H), 6.95 (td, *J* = 7.4, 1.0 Hz, 1H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.50-6.46 (m, 0.27H), 6.44-6.37 (m, 0.27H), 3.89 (s, 3H), 3.59-3.58 (m, 1.7H); EI-MS (m/z): 231.2. This outcome revealed that there were iterative Ni-(H)D species addition/elimination steps during the reaction process (see Supplementary Figure 1f)



Supplementary Figure 1 Mechanistic studies. **a** Reaction of styrene with phenyldiazomethane did not give the desired product; **b** Reaction of 1,2-diphenylcyclopropane under the standard conditions did not give the desired product; **c** Reaction of 1-methoxy-4-(3-phenylpropyl)benzene under the standard conditions did not give the desired product; **d** Radical scavenger, 2,6-di-*tert*-butyl-4-methylphenol (BHT) added and the reaction was almost unaffected; **e** *N*-Ts hydrazone used instead of simple hydrazone did not give the desired product; **f** H/D exchanges occurred in the isotope experiment



Supplementary Figure 2. ¹H NMR spectra for compound 4aa



Supplementary Figure 3. ¹³C NMR spectra for compound 4aa



Supplementary Figure 4. ¹H NMR spectra for compound 4ab



Supplementary Figure 5. ¹³C NMR spectra for compound 4ab



Supplementary Figure 6. ¹H NMR spectra for compound 4ac



Supplementary Figure 7. ¹³C NMR spectra for compound 4ac



Supplementary Figure 8. ¹H NMR spectra for compound 4ad



Supplementary Figure 9. ¹³C NMR spectra for compound 4ad



Supplementary Figure 10. ¹H NMR spectra for compound 4ae



Supplementary Figure 11. ¹³C NMR spectra for compound 4ae



Supplementary Figure 12. ¹H NMR spectra for compound 4af



Supplementary Figure 13. ¹³C NMR spectra for compound 4af



Supplementary Figure 14. ¹H NMR spectra for compound 4ag


Supplementary Figure 15. ¹³C NMR spectra for compound 4ag



Supplementary Figure 16. ¹H NMR spectra for compound 4ah



Supplementary Figure 17. ¹³C NMR spectra for compound 4ah



Supplementary Figure 18. ¹H NMR spectra for compound 4ai



Supplementary Figure 19. ¹³C NMR spectra for compound 4ai



Supplementary Figure 20. ¹H NMR spectra for compound 4aj



Supplementary Figure 21. ¹³C NMR spectra for compound 4aj



Supplementary Figure 22. ¹⁹F NMR spectra for compound 4aj



Supplementary Figure 23. ¹H NMR spectra for compound 4ak



Supplementary Figure 24. ¹³C NMR spectra for compound 4ak



Supplementary Figure 25. ¹H NMR spectra for compound 4al



Supplementary Figure 26. ¹³C NMR spectra for compound 4al



Supplementary Figure 27. ¹H NMR spectra for compound 4am



Supplementary Figure 28. ¹³C NMR spectra for compound 4am



Supplementary Figure 29. ¹H NMR spectra for compound 4an



Supplementary Figure 30. ¹³C NMR spectra for compound 4an



Supplementary Figure 31. ¹H NMR spectra for compound 4ao



Supplementary Figure 32. ¹³C NMR spectra for compound 4ao



Supplementary Figure 33. ¹³C NMR spectra for compound 4ap



Supplementary Figure 34. ¹³C NMR spectra for compound 4ap



Supplementary Figure 35. ¹H NMR spectra for compound 4aq and 4aq'



Supplementary Figure 36. ¹³C NMR spectra for compound 4aq and 4aq'



Supplementary Figure 37. ¹H NMR spectra for compound 4ar and 4ar'



Supplementary Figure 38. ¹³C NMR spectra for compound 4ar and 4ar'



Supplementary Figure 39. ¹H NMR spectra for compound 4ba



Supplementary Figure 40. ¹³C NMR spectra for compound 4ba



Supplementary Figure 41. ¹H NMR spectra for compound 4bb



Supplementary Figure 42. ¹³C NMR spectra for compound 4bb



Supplementary Figure 43. ¹H NMR spectra for compound 4bc



Supplementary Figure 44. ¹³C NMR spectra for compound 4bc



Supplementary Figure 45. ¹H NMR spectra for compound 4bd



Supplementary Figure 46. ¹³C NMR spectra for compound 4bd



Supplementary Figure 47. ¹H NMR spectra for compound 4be



Supplementary Figure 48. ¹³C NMR spectra for compound 4be



Supplementary Figure 49. ¹H NMR spectra for compound 4bf



Supplementary Figure 50. ¹³C NMR spectra for compound 4bf


Supplementary Figure 51. ¹H NMR spectra for compound 4bg



Supplementary Figure 52. ¹³C NMR spectra for compound 4bg



Supplementary Figure 53. ¹H NMR spectra for compound 4bh



Supplementary Figure 54. ¹³C NMR spectra for compound 4bh



Supplementary Figure 55. ¹H NMR spectra for compound 4bi



Supplementary Figure 56. ¹³C NMR spectra for compound 4bi



Supplementary Figure 57. ¹H NMR spectra for compound 4bj



Supplementary Figure 58. ¹³C NMR spectra for compound 4bj



Supplementary Figure 59. ¹⁹F NMR spectra for compound 4bj



Supplementary Figure 60. ¹H NMR spectra for compound 4bk



Supplementary Figure 61. ¹³C NMR spectra for compound 4bk



Supplementary Figure 62. ¹⁹F NMR spectra for compound 4bk



Supplementary Figure 63. ¹H NMR spectra for compound 4bl



Supplementary Figure 64. ¹³C NMR spectra for compound 4bl



8 1.30 8 1.30 8 1.30 9

Supplementary Figure 65. ¹H NMR spectra for compound 4bm



Supplementary Figure 66. ¹³C NMR spectra for compound 4bm



Supplementary Figure 67. ¹H NMR spectra for compound 4bn



Supplementary Figure 68. ¹³C NMR spectra for compound 4bn



Supplementary Figure 69. ¹H NMR spectra for compound 4bo



Supplementary Figure 70. ¹³C NMR spectra for compound 4bo



Supplementary Figure 71. ¹H NMR spectra for compound 4bp



Supplementary Figure 72. ¹³C NMR spectra for compound 4bp



Supplementary Figure 73. ¹H NMR spectra for compound 4bq



Supplementary Figure 74. ¹³C NMR spectra for compound 4bq



Supplementary Figure 75. ¹H NMR spectra for compound 4br



Supplementary Figure 76. ¹³C NMR spectra for compound 4br



Supplementary Figure 77. ¹H NMR spectra for compound 4ca



Supplementary Figure 78. ¹³C NMR spectra for compound 4ca



Supplementary Figure 79. ¹H NMR spectra for compound 4cb



Supplementary Figure 80. ¹³C NMR spectra for compound 4ca



Supplementary Figure 81. ¹H NMR spectra for compound 4cc



Supplementary Figure 82. ¹³C NMR spectra for compound 4cc



Supplementary Figure 83. ¹H NMR spectra for compound 4cd



Supplementary Figure 84. ¹³C NMR spectra for compound 4cd



Supplementary Figure 85. ¹H NMR spectra for compound 4ce



Supplementary Figure 86. ¹³C NMR spectra for compound 4ce


Supplementary Figure 87. ¹H NMR spectra for compound 4cf



Supplementary Figure 88. ¹³C NMR spectra for compound 4cf



Supplementary Figure 89. ¹H NMR spectra for compound 4cg



Supplementary Figure 90. ¹³C NMR spectra for compound 4cg



Supplementary Figure 91. ¹H NMR spectra for compound 4ch



Supplementary Figure 92. ¹³C NMR spectra for compound 4ch



Supplementary Figure 93. ¹H NMR spectra for compound 4ci



Supplementary Figure 94. ¹³C NMR spectra for compound 4ci



Supplementary Figure 95. ¹⁹F NMR spectra for compound 4ci



Supplementary Figure 96. ¹H NMR spectra for compound 4cj



Supplementary Figure 97. ¹³C NMR spectra for compound 4cj



Supplementary Figure 98. ¹H NMR spectra for compound 4ck



Supplementary Figure 99. ¹³C NMR spectra for compound 4ck



Supplementary Figure 100. ¹H NMR spectra for compound 4cl



Supplementary Figure 101. ¹³C NMR spectra for compound 4cl



Supplementary Figure 102. ¹H NMR spectra for compound 4cm



Supplementary Figure 103. ¹³C NMR spectra for compound 4cm



Supplementary Figure 104. ¹H NMR spectra for compound 4cn



Supplementary Figure 105. ¹³C NMR spectra for compound 4cn



Supplementary Figure 106. ¹H NMR spectra for compound 4co



Supplementary Figure 107. ¹³C NMR spectra for compound 4co



Supplementary Figure 108. ¹H NMR spectra for compound 4cp



Supplementary Figure 109. ¹³C NMR spectra for compound 4cp



Supplementary Figure 110. ¹H NMR spectra for compound 4cq



Supplementary Figure 111. ¹³C NMR spectra for compound 4cq



Supplementary Figure 112. ¹H NMR spectra for compound 4cr



Supplementary Figure 113. ¹H NMR spectra for compound 4cr



Supplementary Figure 114. ¹H NMR spectra for compound 4cs



Supplementary Figure 115. ¹³C NMR spectra for compound 4cs



Supplementary Figure 116. ¹H NMR spectra for compound 6



Supplementary Figure 117. ¹³C NMR spectra for compound 6



Supplementary Figure 118. ¹H NMR spectra for compound 8



Supplementary Figure 119. ¹³C NMR spectra for compound 8



Supplementary Figure 120. ¹H NMR spectra for compound 10



Supplementary Figure 121. ¹³C NMR spectra for compound 10



Supplementary Figure 122. ¹H NMR spectra for compound 12


Supplementary Figure 123. ¹³C NMR spectra for compound 12



Supplementary Figure 124. ¹H NMR spectra for compound 14



Supplementary Figure 125. ¹³C NMR spectra for compound 14



Supplementary Figure 126. ¹H NMR spectra for compound 16



Supplementary Figure 127. ¹³C NMR spectra for compound 16



Supplementary Figure 128. ¹H NMR spectra for compound 18



Supplementary Figure 129. ¹³C NMR spectra for compound 18



Supplementary Figure 130. ¹H NMR spectra for compound 20



Supplementary Figure 131. ¹³C NMR spectra for compound 20



Supplementary Figure 132. ¹H NMR spectra for compound 4ca-D7

Supplementary References

[1] Hamasaka, G., Sakurai, F. & Uozumi, Y. A palladium NNC-Pincer complex: an efficient catalyst for allylic arylation at parts per billion levels. *Chem. Commun.* **51**, 3886-3888 (2015).

[2] Yang, H., Yan, H., Sun, P., Zhu, Y., Lu, L., Liu, D., Rong, G. & Mao, J. Iron-catalyzed direct alkenylation of sp³(C-H) bonds via decarboxylation of cinnamic acids under ligand-free conditions. *Green Chem.* 15, 976-981 (2013).

[3] Jin, W., Wong, W.-T. & Law, G.-L. A simple and direct method for the palladium-catalyzed oxidative coupling of unactivated allylarenes with classic arenes. *Chem. Cat. Chem.* **6**, 1599-1603 (2014).

[4] Werner, E. W. & Sigman, M. S. Operationally simple and highly (*E*)-styrenyl-selective Heck reactions of electronically nonbiased olefins. *J. Am. Chem. Soc.* **133**, 9692-9695 (2011).

[5] Cai, Y., Benischke, A. D., Knochel, P. & Gosmini, C. Cobalt-catalyzed reductive cross-coupling between styryl and benzyl halides. *Chem.- Eur. J.* 23, 250-253 (2017).

[6] Lei, C., Yip, Y. J. & Zhou, J. S. Nickel-catalyzed direct synthesis of aryl olefins from ketones and organoboron reagents under neutral conditions. *J. Am. Chem. Soc.* **139**, 6086-6089 (2017).

[7] Pérez-Aguilar, M. C. & Valdés, C. Olefination of carbonyl compounds through reductive coupling of alkenylboronic acids and tosylhydrazones. *Angew. Chem. Int. Ed.* **51**, 5953-5957 (2012).

[8] Zhou, B., Sato, H., Ilies, L. & Nakamura, E. Iron-catalyzed remote arylation of aliphatic C-H bond via 1,5-hydrogen shift. *ACS Catalysis* **8**, 8-11 (2018).

[9] Jia, X.-G., Guo, P., Duan, J. & Shu, X.-Z. Dual nickel and lewis acid catalysis for cross-electrophile coupling: the allylation of aryl halides with allylic alcohols. *Chem. Sci.* **9**, 640-645 (2018).

[10] Ricardo, C. L., Mo, X., McCubbin, J. A. & Hall, D. G. A surprising substituent effect provides a superior boronic acid catalyst for mild and metal-free direct Friedel-Crafts alkylations and prenylations of neutral arenes. *Chem.- Eur. J.* **21**, 4218-4223 (2015).

[11] Alacid, E. & Nájera, C. Palladium-catalyzed cross-coupling reactions of potassium alkenyltrifluoroborates with organic halides in aqueous media. *J. Org. Chem.* **74**, 2321-2327 (2009).

[12] Tao, J.-L., Yang, B. & Wang, Z.-X. Pincer-nickel-catalyzed allyl-aryl coupling between allyl methyl ethers and arylzinc chlorides. *J. Org. Chem.* **80**, 12627-12634 (2015).

[13] Chan, C.-K., Tsai, Y.-L. & Chang, M.-Y. Bi(OTf)₃ catalyzed disproportionation reaction of cinnamyl alcohols. *Tetrahedron* **73**, 3368-3376 (2017).

[14] Mino, T., Kogure, T., Abe, T., Koizumi, T., Fujita, T. & Sakamoto, M. Palladium-catalyzed allylic arylation of allylic ethers with arylboronic acids using hydrazone ligands. *Eur. J. Org. Chem.* 1501-1505 (2013).

[15] Onodera, G., Imajima, H., Yamanashi, M., Nishibayashi, Y., Hidai, M. & Uemura, S. Ruthenium-catalyzed allylation of aromatic compounds and allylic ether formation. *Organometallics* **23**, 5841-5848 (2004).

[16] Yoshimitsu, T., Arano, Y. & Nagaoka, H. Radical α-C-H hydroxyalkylation of ethers and acetal. *J. Org. Chem.*70, 2342-2345 (2005).

[17] Li, G., Wu, L., Lv, G., Liu, H., Fu, Q., Zhang, X. & Tang, Z. Alkyl transfer from C-C cleavage: replacing the nitro group of nitro-olefins. *Chem. Commun.* **50**, 6246-6248 (2014).

[18] Wang, G.-Z., Shang, R., Cheng, W.-M. & Fu, Y. Irradiation-induced Heck reaction of unactivated alkyl halides at room temperature. *J. Am. Chem. Soc.* **139**, 18307-18312 (2017).

[19] Nazari, S. H., Bourdeau, J. E., Talley, M. R., Valdivia-Berroeta, G. A., Smith, S. J. & Michaelis, D. J. Nickel-catalyzed Suzuki cross couplings with unprotected allylic alcohols enabled by bidentate *N*-heterocyclic carbene (NHC)/phosphine ligands. *ACS Catalysis* **8**, 86-89 (2018).

[20] Friscourt, F., Fahrni, C. J. & Boons, G.-J. Fluorogenic strain-promoted alkyne–diazo cycloadditions. *Chem.-Eur. J.* **21**, 13996-14001 (2015)

[21] Barluenga, J., Quiñones, N., Tom ás-Gamasa, M. & Cabal, M.-P. Intermolecular metal-free cyclopropanation of alkenes using tosylhydrazones. *Eur. J. Org. Chem.* 2312-2317 (2012).

[22] Lv, L., Qiu, Z., Li, J., Liu, M. & Li, C.-J. N₂H₄ as traceless mediator for homo- and cross- aryl coupling. *Nat. Commun.* 9, 4739 (2018).